~105,000 people in the U.S. are on the waitlist for a life-saving organ transplant.
~50% of patients on the waitlist will not receive the organ they need.
~17 people in the U.S. die each day due to the lack of available organs.
At Miromatrix, we are pioneering a novel technology with the goal of developing fully transplantable human organs. Using the science behind our patented technology, we are working to develop bioengineered human organs in hopes of providing new options for transplantation. We believe our approach may provide an efficient way to answer the unmet need of thousands of patients across the country who will otherwise go without the transplant they need to survive and thrive.
Our Technology
Our proprietary perfusion decellularization and recellularization technology harnesses the powerful evolutionary forces shaping complex organ development and the regenerative capabilities of living human cells.
How it Works
Cells are removed from a pig organ using a safe wash process that leaves a non-cellular matrix with the appropriate organ architecture. Human cells are then introduced into the matrix to bioengineer a new human organ. Once optimized, we believe the bioengineered organ will be able to be implanted into the patients using existing transplantation techniques and equipment.